Glenmede Investment Management LP Has $159.51 Million Stock Holdings in Abbott Laboratories $ABT

Glenmede Investment Management LP lowered its position in shares of Abbott Laboratories (NYSE:ABT) by 4.9% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,190,887 shares of the healthcare product maker’s stock after selling 61,675 shares during the quarter. Abbott Laboratories accounts for about 0.8% of Glenmede Investment Management LP’s investment portfolio, making the stock its 25th biggest holding. Glenmede Investment Management LP owned about 0.07% of Abbott Laboratories worth $159,507,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of ABT. Vanguard Group Inc. boosted its position in shares of Abbott Laboratories by 1.8% during the second quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock worth $23,502,644,000 after purchasing an additional 2,977,715 shares in the last quarter. State Street Corp increased its position in shares of Abbott Laboratories by 0.9% in the 2nd quarter. State Street Corp now owns 78,354,270 shares of the healthcare product maker’s stock valued at $10,656,964,000 after buying an additional 689,517 shares in the last quarter. Capital International Investors raised its stake in Abbott Laboratories by 2.5% during the 3rd quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker’s stock worth $8,251,974,000 after buying an additional 1,478,076 shares during the period. Norges Bank bought a new position in Abbott Laboratories during the second quarter worth about $3,026,180,000. Finally, Massachusetts Financial Services Co. MA grew its stake in Abbott Laboratories by 5.8% in the third quarter. Massachusetts Financial Services Co. MA now owns 15,096,907 shares of the healthcare product maker’s stock valued at $2,022,080,000 after acquiring an additional 821,325 shares during the period. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ABT. Evercore dropped their price target on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. William Blair upgraded Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, November 20th. The Goldman Sachs Group lowered their target price on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a research note on Friday, January 23rd. Barclays dropped their target price on shares of Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating on the stock in a report on Monday, February 2nd. Finally, Raymond James Financial reduced their price target on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $136.16.

Abbott Laboratories Price Performance

NYSE:ABT opened at $107.99 on Friday. Abbott Laboratories has a 52-week low of $105.27 and a 52-week high of $139.06. The company has a market cap of $187.66 billion, a P/E ratio of 29.03, a P/E/G ratio of 1.72 and a beta of 0.74. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58. The stock’s 50-day simple moving average is $114.58 and its 200 day simple moving average is $123.91.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting the consensus estimate of $1.50. The firm had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The business’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, sell-side analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 67.74%.

Insider Buying and Selling at Abbott Laboratories

In other news, SVP Eric Shroff sold 709 shares of Abbott Laboratories stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $81,946.22. Following the completion of the transaction, the senior vice president owned 39,164 shares of the company’s stock, valued at $4,526,575.12. This trade represents a 1.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Daniel J. Starks acquired 10,000 shares of the stock in a transaction dated Wednesday, February 4th. The shares were purchased at an average price of $108.73 per share, for a total transaction of $1,087,300.00. Following the completion of the purchase, the director directly owned 6,738,817 shares in the company, valued at $732,711,572.41. The trade was a 0.15% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders sold 3,055 shares of company stock valued at $353,097 in the last 90 days. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.